Development and safety of PI3K inhibitors in cancer
Archives of Toxicology · 2023-03 · 97 (3) · 635-650
DOI: 10.1007/s00204-023-03440-4 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Archives of Toxicology, online erschienen am 11.02.2023. Verfasst von Miaomiao Yu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, …. Hauptthemen laut MEDLINE: Neoplasms, Drug-Related Side Effects and Adverse Reactions, Antineoplastic Agents. Die Arbeit wurde bisher 104-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
The phosphatidylinositol 3-kinase (PI3K) signalling pathway regulates cell survival, proliferation, migration, metabolism and other vital cellular life processes. In addition, activation of the PI3K signalling pathway is important for cancer development. As a result, a variety of PI3K inhibitors have been clinically developed to treat malignancies. Although several PI3K inhibitors have received approval from the Food and Drug Administration (FDA) for significant antitumour activity, frequent and severe adverse effects have greatly limited their clinical application. These toxicities are mostly on-target and immune-mediated; nevertheless, the underlying mechanisms are still unclear. Current management usually involves intervention through symptomatic treatment, with discontinuation if toxicity persists. Therefore, it is necessary to comprehensively understand these adverse events and ensure the clinical safety application of PI3K inhibitors by establishing the most effective management guidelines, appropriate intermittent dosing regimens and new combination administration. Here, the focus is on the development of PI3K inhibitors in cancer therapy, with particular emphasis on isoform-specific PI3K inhibitors. The most common adverse effects of PI3K inhibitors are also covered, as well as potential mechanisms and management approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Zijingang Campus, Hangzhou, 310058, Zhejiang, People's Republic of Chi…
- Institute of Pharmacology & Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, Zhejiang, People's Republic of China.
- Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou, 310018, Zhejiang, People's Republic of China.
- Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, People's Republic of China.
ORCID-Profile: Hao Yan
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Yu, M., Chen, J., Xu, Z., Yang, B., He, Q., Luo, P., Yan, H., & Yang, X. (2023). Development and safety of PI3K inhibitors in cancer. Archives of Toxicology, 97(3), 635-650. https://doi.org/10.1007/s00204-023-03440-4
Vancouver
Yu M, Chen J, Xu Z, Yang B, He Q, Luo P, et al. Development and safety of PI3K inhibitors in cancer. Archives of Toxicology. 2023;97(3):635-650. doi:10.1007/s00204-023-03440-4
BibTeX
@article{Yu2023,
author = {Yu, Miaomiao and Chen, Jiajia and Xu, Zhifei and Yang, Bo and He, Qiaojun and Luo, Peihua and Yan, Hao and Yang, Xiaochun},
title = {Development and safety of PI3K inhibitors in cancer},
journal = {Archives of Toxicology},
year = {2023},
volume = {97},
number = {3},
pages = {635--650},
doi = {10.1007/s00204-023-03440-4}
}
EUVIMED